Theo Rispens

18.5k total citations · 6 hit papers
273 papers, 11.7k citations indexed

About

Theo Rispens is a scholar working on Immunology, Radiology, Nuclear Medicine and Imaging and Rheumatology. According to data from OpenAlex, Theo Rispens has authored 273 papers receiving a total of 11.7k indexed citations (citations by other indexed papers that have themselves been cited), including 134 papers in Immunology, 121 papers in Radiology, Nuclear Medicine and Imaging and 78 papers in Rheumatology. Recurrent topics in Theo Rispens's work include Monoclonal and Polyclonal Antibodies Research (121 papers), Rheumatoid Arthritis Research and Therapies (43 papers) and Glycosylation and Glycoproteins Research (40 papers). Theo Rispens is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (121 papers), Rheumatoid Arthritis Research and Therapies (43 papers) and Glycosylation and Glycoproteins Research (40 papers). Theo Rispens collaborates with scholars based in Netherlands, United States and United Kingdom. Theo Rispens's co-authors include Gestur Vidarsson, Gillian Dekkers, Gertjan Wolbink, Rob C. Aalberse, Janine Schuurman, Steven O. Stapel, Pauline A. van Schouwenburg, Manfred Wuhrer, Pleuni Ooijevaar‐de Heer and Desirée van der Kleij and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Theo Rispens

261 papers receiving 11.4k citations

Hit Papers

IgG Subclasses and Allotypes: From Structure to Effector ... 2009 2026 2014 2020 2014 2009 2015 2020 2023 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. IgG Subclasses and Allotypes: From Structure to Effector Functions
    2014 1.9k citations Gestur Vidarsson, Gillian Dekkers et al. profile →
  2. Immunoglobulin G4: an odd antibody
    2009 622 citations Rob C. Aalberse, Theo Rispens et al. profile →
  3. Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
    2015 304 citations Theo Rispens et al. profile →
  4. MS-Based Allotype-Specific Analysis of Polyclonal IgG-Fc N-Glycosylation
    2020 260 citations Steven W. de Taeye, Theo Rispens et al. profile →
  5. The unique properties of IgG4 and its roles in health and disease
    2023 116 citations Theo Rispens et al. profile →
  6. Impact of structural modifications of IgG antibodies on effector functions
    2024 47 citations Maximilian Brinkhaus, Theo Rispens et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Theo Rispens Netherlands 56 5.0k 4.3k 3.2k 2.6k 1.6k 273 11.7k
Thomas Dörner Germany 74 10.5k 2.1× 4.3k 1.0× 2.7k 0.8× 7.2k 2.8× 1.3k 0.8× 371 19.2k
Robert P. Kimberly United States 71 9.2k 1.8× 4.4k 1.0× 5.3k 1.7× 5.0k 2.0× 1.7k 1.0× 223 18.0k
Judith A. James United States 56 6.7k 1.3× 2.7k 0.6× 1.9k 0.6× 6.6k 2.6× 1.7k 1.1× 268 12.6k
Gregg J. Silverman United States 51 6.5k 1.3× 2.4k 0.6× 2.9k 0.9× 1.8k 0.7× 1.1k 0.7× 191 10.9k
Brian L. Kotzin United States 59 8.5k 1.7× 2.3k 0.5× 1.7k 0.5× 3.8k 1.5× 1.3k 0.8× 175 13.5k
Robert B. Nussenblatt United States 76 5.2k 1.0× 2.0k 0.5× 2.8k 0.9× 5.1k 2.0× 4.1k 2.5× 435 25.1k
Sylviane Muller France 58 5.3k 1.1× 2.4k 0.6× 7.0k 2.2× 2.2k 0.8× 2.3k 1.4× 319 15.9k
V. Michael Holers United States 85 13.5k 2.7× 4.0k 0.9× 4.2k 1.3× 6.8k 2.7× 1.8k 1.1× 434 24.7k
Anthony W. Purcell Australia 65 8.9k 1.8× 2.1k 0.5× 6.7k 2.1× 1.1k 0.4× 1.8k 1.1× 320 16.6k
Jan G. J. van de Winkel Netherlands 70 8.9k 1.8× 8.2k 1.9× 5.6k 1.7× 1.0k 0.4× 1.5k 0.9× 246 17.2k

Countries citing papers authored by Theo Rispens

Since Specialization
Citations

This map shows the geographic impact of Theo Rispens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Theo Rispens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Theo Rispens more than expected).

Fields of papers citing papers by Theo Rispens

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Theo Rispens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Theo Rispens. The network helps show where Theo Rispens may publish in the future.

Co-authorship network of co-authors of Theo Rispens

This figure shows the co-authorship network connecting the top 25 collaborators of Theo Rispens. A scholar is included among the top collaborators of Theo Rispens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Theo Rispens. Theo Rispens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wolbink, Gertjan, Michael T. Nurmohamed, Maarten Boers, et al.. (2025). Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial. Annals of the Rheumatic Diseases. 84(8). 1293–1300.
2.
Borgers, Jessica S.W., Kyra A. Gelderman, Theo Rispens, et al.. (2024). Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma. Journal for ImmunoTherapy of Cancer. 12(6). e009215–e009215. 8 indexed citations
3.
Boer, Marjon A. de, et al.. (2024). Concentrations of subcutaneously administered belimumab in human breast milk of a woman with systemic lupus erythematosus: a case report. Lupus Science & Medicine. 11(1). e001167–e001167. 3 indexed citations
4.
Kempen, Zoé L. E. van, Eileen W Stalman, Laura Kummer, et al.. (2023). Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod. Multiple Sclerosis Journal. 30(3). 443–447. 1 indexed citations
5.
Bloem, Karien, et al.. (2023). Drug-tolerant detection of anti-drug antibodies in an antigen-binding assay using europium chelate fluorescence. Journal of Immunological Methods. 514. 113436–113436. 4 indexed citations
6.
Brinkhaus, Maximilian, Arthur E. H. Bentlage, Ninotska I. L. Derksen, et al.. (2022). The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement. Nature Communications. 13(1). 6073–6073. 27 indexed citations
7.
Heer, Pleuni Ooijevaar‐de, Ninotska I. L. Derksen, Simone Kruithof, et al.. (2022). At Critically Low Antigen Densities, IgM Hexamers Outcompete Both IgM Pentamers and IgG1 for Human Complement Deposition and Complement-Dependent Cytotoxicity. The Journal of Immunology. 209(1). 16–25. 13 indexed citations
8.
Dekkers, Gillian, Mieke C. Brouwer, Gerard van Mierlo, et al.. (2020). Unraveling the Effect of a Potentiating Anti–Factor H Antibody on Atypical Hemolytic Uremic Syndrome–Associated Factor H Variants. The Journal of Immunology. 205(7). 1778–1786. 5 indexed citations
9.
Taeye, Steven W. de, Erik L. de Graaf, Gillian Dekkers, et al.. (2019). Functional Attributes of Antibodies, Effector Cells, and Target Cells Affecting NK Cell–Mediated Antibody-Dependent Cellular Cytotoxicity. The Journal of Immunology. 203(12). 3126–3135. 49 indexed citations
10.
Dekkers, Gillian, Fleur S. van de Bovenkamp, Arthur E. H. Bentlage, et al.. (2019). Human DC-SIGN and CD23 do not interact with human IgG. Scientific Reports. 9(1). 9995–9995. 38 indexed citations
11.
Bovenkamp, Fleur S. van de, Ninotska I. L. Derksen, Pleuni Ooijevaar‐de Heer, et al.. (2018). Adaptive antibody diversification through N -linked glycosylation of the immunoglobulin variable region. Proceedings of the National Academy of Sciences. 115(8). 1901–1906. 99 indexed citations
12.
Derksen, Ninotska I. L., et al.. (2018). Dimeric IgG complexes from IVIg are incapable of inducing in vitro neutrophil degranulation or complement activation. PLoS ONE. 13(4). e0195729–e0195729. 5 indexed citations
13.
Bruggeman, Christine W., Gillian Dekkers, Arthur E. H. Bentlage, et al.. (2017). Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile. The Journal of Immunology. 199(1). 204–211. 64 indexed citations
14.
Kempen, Zoé L. E. van, Cyra E Leurs, Birgit I. Lissenberg‐Witte, et al.. (2017). The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing. Multiple Sclerosis Journal. 24(6). 805–810. 28 indexed citations
15.
Krieckaert, C., Michael T. Nurmohamed, Ronald van Vollenhoven, et al.. (2017). Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. Annals of the Rheumatic Diseases. 77(4). 484–487. 53 indexed citations
16.
Verheul, Marije K., Peter A. van Veelen, Arnoud de Ru, et al.. (2017). Pitfalls in the detection of citrullination and carbamylation. Autoimmunity Reviews. 17(2). 136–141. 38 indexed citations
17.
Schie, Karin A. van, et al.. (2016). Therapeutic TNF Inhibitors can Differentially Stabilize Trimeric TNF by Inhibiting Monomer Exchange. Scientific Reports. 6(1). 32747–32747. 46 indexed citations
18.
Bovenkamp, Fleur S. van de, Lise Hafkenscheid, Theo Rispens, & Yoann Rombouts. (2016). The Emerging Importance of IgG Fab Glycosylation in Immunity. The Journal of Immunology. 196(4). 1435–1441. 234 indexed citations
19.
Schaardenburg, Dirkjan van, Pleuni Ooijevaar‐de Heer, Michel Tsang-A-Sjoe, et al.. (2016). Anti-Hinge Antibodies Recognize IgG Subclass– and Protease-Restricted Neoepitopes. The Journal of Immunology. 198(1). 82–93. 23 indexed citations
20.
Rispens, Theo, Anna M. Davies, Pleuni Ooijevaar‐de Heer, et al.. (2014). Dynamics of Inter-heavy Chain Interactions in Human Immunoglobulin G (IgG) Subclasses Studied by Kinetic Fab Arm Exchange. Journal of Biological Chemistry. 289(9). 6098–6109. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas Dörner Breakdown of academic impact, for papers by Robert P. Kimberly Breakdown of academic impact, for papers by Judith A. James Breakdown of academic impact, for papers by Gregg J. Silverman Breakdown of academic impact, for papers by Brian L. Kotzin Breakdown of academic impact, for papers by Robert B. Nussenblatt Breakdown of academic impact, for papers by Sylviane Muller Breakdown of academic impact, for papers by V. Michael Holers Breakdown of academic impact, for papers by Anthony W. Purcell Breakdown of academic impact, for papers by Jan G. J. van de Winkel
Rankless by CCL
2026